BAX and renal cell carcinoma: On the other hand, sorafenib, a multikinase inhibitor approved for the treatment of advanced RCC, induces apoptosis by ROS production, and such ROS-dependent apoptotic processes are independent of caspase activities and Bcl-2 family proteins, including bax and bak; however, sorafenib-induced ROS accumulation mediates increased caspase-8 activation [150].